	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	2,359	2,813	3,282	3,142	2,867	3,155	3,258	3,746	4,619	5,395	5,797	6,204	7,662	8,897	9,646
Cost of Operating Revenue	1,109	1,334	1,409	1,513	1,415	1,488	1,515	1,649	2,120	2,218	2,580	2,952	3,417	3,680	3,241
Gross Profit	1,250	1,479	1,873	1,629	1,452	1,667	1,743	2,097	2,499	3,177	3,217	3,252	4,246	5,217	6,405
Gross Margin	53.0	52.6	57.1	51.8	50.6	52.8	53.5	56.0	54.1	58.9	55.5	52.4	55.4	58.6	66.4
Total Operating Expenses	1,911	2,274	2,573	2,789	2,698	2,895	2,980	3,216	3,878	4,079	4,738	5,505	6,731	7,543	8,086
Operating Profit	449	539	709	353	169	260	277	530	741	1,316	1,058	700	932	1,354	1,560
Operating Margin	19.0	19.2	21.6	11.2	5.9	8.2	8.5	14.1	16.0	24.4	18.3	11.3	12.2	15.2	16.2
Financing Income/(Expense) - Net	-86	-87	-83	1	-53	11	-1	-1	6	80	67	15	56	14	-76
Profit before Taxes	364	454	631	361	117	270	291	546	739	1,381	1,115	745	843	1,131	1,573
Income Taxes	88	130	152	102	20	68	51	104	135	240	225	253	313	344	381
Profit after Tax	277	324	479	254	93	195	239	445	606	1,140	884	471	547	738	1,141
PAT Margin	11.7	11.5	14.6	8.1	3.2	6.2	7.3	11.9	13.1	21.1	15.3	7.6	7.1	8.3	11.8
EPS - Basic - ex Extraordinary Items	10.99	12.82	18.96	10.07	3.69	7.71	9.49	17.61	23.99	45.01	34.85	18.58	21.57	29.08	44.98
EPS - Diluted - ex Extraordinary Items	10.99	12.82	18.96	10.07	3.69	7.71	9.49	17.61	23.98	45.01	34.85	18.58	21.57	29.08	44.98
EBIT	449	539	709	353	169	260	277	530	741	1,316	1,058	700	932	1,354	1,560
EBITDA	521	626	812	532	332	433	455	712	951	1,525	1,291	961	1,289	1,751	1,979
EBITDA Margin	22.1	22.2	24.7	16.9	11.6	13.7	14.0	19.0	20.6	28.3	22.3	15.5	16.8	19.7	20.5

Balance Sheet

Abridged

Understanding Balance Sheet

Ipca Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	1,210	1,397	1,602	1,935	1,622	1,734	1,945	2,378	2,856	3,437	4,457	5,189	5,539	5,967	6,374
Long-Term Investments	2	1	1	3	0	0	-	-	38	34	155	173	147	25	122
Property Plant & Equipment - Net	1,005	1,179	1,447	1,953	2,036	1,976	1,895	1,783	1,993	2,146	2,503	2,695	4,663	4,685	5,202
Total Non-Current Assets	1,094	1,300	1,608	2,190	2,270	2,226	2,172	2,173	2,404	2,631	3,166	3,437	5,562	5,794	5,997
Total Assets	2,327	2,697	3,210	4,125	3,892	3,960	4,117	4,551	5,260	6,068	7,624	8,626	11,101	11,761	12,370
Total Current Liabilities	640	634	793	1,252	970	956	1,008	1,098	1,326	1,161	1,466	1,806	2,356	2,386	2,307
Long Term Debt	330	366	294	499	484	352	234	141	116	17	407	669	620	594	196
Total Non-Current Liabilities	433	510	457	676	663	548	421	315	292	192	616	905	1,019	986	539
Total Liabilities	1,073	1,143	1,251	1,928	1,633	1,504	1,429	1,413	1,619	1,352	2,082	2,711	3,374	3,372	2,846
Total Shareholders' Equity	1,254	1,554	1,960	2,197	2,259	2,455	2,689	3,122	3,627	4,702	5,465	5,842	6,332	6,948	8,064
Minority Interest	-	-	-	-	-	-	-	16	14	15	77	73	1,395	1,440	1,460
Total Equity	1,254	1,554	1,960	2,197	2,259	2,455	2,689	3,138	3,641	4,716	5,542	5,915	7,727	8,388	9,524
Total Liabilities & Equity	2,327	2,697	3,210	4,125	3,892	3,960	4,117	4,551	5,260	6,068	7,624	8,626	11,101	11,761	12,370

Cash Flow

Abridged

Understanding Cash Flow Statement

Ipca Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	413	463	621	460	276	369	399	612	856	1,340	1,156	770	983	1,447	1,386
Working Capital - Increase/(Decrease)	-87	-100	-104	-6	410	-104	-80	-122	-264	-236	-273	49	-92	-176	-294
Net CF from Operating Activities	325	362	517	454	686	265	319	490	593	1,104	883	819	891	1,271	1,092
Capital Expenditures - Net	259	228	391	557	246	134	136	179	294	359	476	458	403	770	317
Net CF from Investing Activities	-296	-270	-395	-709	-227	-156	-136	-171	-552	-542	-888	-779	-1,373	-894	-278
Dividends Paid - Cash - Total	47	47	66	37	15	0	15	15	122	102	101	101	51	101	52
Stock - Issuance/(Retirement) - Net	1	0	-	-	-	-	-	5	12	36	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	13	0	-39	321	-414	-135	-93	-175	-6	-232	534	650	-368	-107	-620
Net Cash Flow from Financing Activities	-33	-47	-106	285	-430	-136	-108	-167	-116	-297	433	549	-418	-209	-672
Free Cash Flow to Equity	79	134	87	218	26	-4	91	137	293	513	941	1,010	121	394	155
Free Operating CF net dividend	18	86	59	-142	423	129	167	294	165	640	302	223	429	394	383
Free Operating CF	65	133	125	-105	439	129	182	310	286	742	404	324	480	495	436

Business Segment Analysis

FY End:

Mar 25

Ipca Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 775.57 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 8,896.81 Cr

Assets

Pharmaceuticals (100.0%)₹ 11,760.55 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 1,353.51 Cr

Regional Segment Analysis

FY End:

Mar 25

Ipca Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Outside India (54.8%)₹ 4,897.57 CrIndia (45.2%)₹ 4,042.02 Cr

Historical Segment Analysis

Track how Ipca Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	306	362	479	494	411	776

Frequently Asked Questions

What is the revenue of Ipca Laboratories Ltd.?

The latest trailing twelve month revenue of Ipca Laboratories Ltd. is ₹ 9,646.33 Cr, reflecting a 1-year growth of 8.42% and a 3-year CAGR of 15.85%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Ipca Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Ipca Laboratories Ltd. is ₹ 1,141.12 Cr, with a 3-year earnings CAGR of 34.28%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Ipca Laboratories Ltd.?

The trailing twelve month EBITDA of Ipca Laboratories Ltd. is approximately ₹ 1,560.44 Cr (based on an operating margin of 16.18%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Ipca Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Ipca Laboratories Ltd. is 44.98. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Ipca Laboratories Ltd.?

The debt-to-equity ratio of Ipca Laboratories Ltd. stands at 0.10. The interest coverage ratio is 20.55x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Ipca Laboratories Ltd.?

The estimated book value per share of Ipca Laboratories Ltd. is 326.54 (derived from a P/B ratio of 5.41 and market price of ₹ 1,765.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Ipca Laboratories Ltd.?

The trailing twelve month operating cash flow of Ipca Laboratories Ltd. is ₹ 1,091.85 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Ipca Laboratories Ltd. report consolidated or standalone financials?

Ipca Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.